Search

Your search keyword '"Vapiwala, Neha"' showing total 1,074 results
Start Over Author "Vapiwala, Neha"
1,074 results on '"Vapiwala, Neha"'

203. Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease

Author

Schatz, Alyssa A., primary, Oliver, Thomas K., additional, Swarm, Robert A., additional, Paice, Judith A., additional, Darbari, Deepika S., additional, Dowell, Deborah, additional, Meghani, Salimah H., additional, Winckworth-Prejsnar, Katy, additional, Bruera, Eduardo, additional, Plovnick, Robert M., additional, Richardson, Lisa, additional, Vapiwala, Neha, additional, Wollins, Dana, additional, Hudis, Clifford A., additional, and Carlson, Robert W., additional

Published
2020
Full Text
View/download PDF

205. Socioeconomic Factors Associated With Burnout Among Oncology Trainees

Author

Ahmed, Awad A., primary, Ramey, Stephen J., additional, Dean, Mary K., additional, Takita, Cristiane, additional, Schwartz, David, additional, Wilson, Lynn D., additional, Vapiwala, Neha, additional, Thomas, Charles R., additional, Shanafelt, Tait D., additional, Deville, Curtiland, additional, Jagsi, Reshma, additional, and Holliday, Emma, additional

Published
2020
Full Text
View/download PDF

211. DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.

Author

Niazi, Tamim, primary, Williams, Scott, additional, Davis, Ian D., additional, Stockler, Martin R., additional, Martin, Andrew James, additional, Hague, Wendy, additional, Bracken, Karen, additional, Gorzeman, Margot, additional, Roncolato, Felicia, additional, Yip, Sonia, additional, Horvath, Lisa, additional, Sengupta, Shomik, additional, Hughes, Simon, additional, McDermott, Raymond S., additional, Catto, James WF, additional, Vapiwala, Neha, additional, Parulekar, Wendy R., additional, and Sweeney, Christopher, additional

Published
2020
Full Text
View/download PDF

212. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

Author

Narayan, Vivek, primary, Gladney, Whitney, additional, Plesa, Gabriela, additional, Vapiwala, Neha, additional, Carpenter, Erica L., additional, Maude, Shannon L., additional, Lal, Priti, additional, Lacey, Simon F., additional, Melenhorst, Jan J., additional, Fraietta, Joseph, additional, Sebro, Ronnie, additional, Farwell, Michael, additional, Moniak, Michael, additional, Gilmore, Joan, additional, Lledo, Lester, additional, Dengel, Karen, additional, Marshall, Amy, additional, Coughlin, Christina Marie, additional, June, Carl H., additional, and Haas, Naomi B., additional

Published
2020
Full Text
View/download PDF

213. Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.

Author

Parikh, Neil Rohit, primary, Chang, Eric M., additional, Nickols, Nicholas George, additional, Rettig, Matthew, additional, Raldow, Ann C., additional, Steinberg, Michael L., additional, Koontz, Bridget F., additional, Vapiwala, Neha, additional, Deville, Curtiland, additional, Feng, Felix Y, additional, Spratt, Daniel Eidelberg, additional, Reiter, Robert Evan, additional, Phillips, Ryan, additional, Tran, Phuoc T., additional, and Kishan, Amar Upadhyaya, additional

Published
2020
Full Text
View/download PDF

215. Reply to A. Vickers et al

Author

Jayadevappa, Ravishankar, primary, Chhatre, Sumedha, additional, Gallo, Joseph J., additional, Wittink, Marsha N., additional, Morales, Knashawn H., additional, Lee, David I., additional, Guzzo, Thomas, additional, Vapiwala, Neha, additional, Wong, Yu-Ning, additional, Newman, Diane K., additional, Van Arsdalen, Keith, additional, Malkowicz, S. Bruce, additional, Schwartz, J. Sanford, additional, and Wein, Alan J., additional

Published
2019
Full Text
View/download PDF

220. Sociodemographic and geographic factors impacting radiotherapy recommendation, initiation, and completion for patients with cancer.

Author

Hogan, Jacob S., Orav, E. John, Vapiwala, Neha, and Lam, Miranda B.

Subjects
*BLACK people, *SOCIODEMOGRAPHIC factors, *CANCER treatment, *RACE, *CANCER hospitals
Abstract

Background Methods Results Conclusions More than half of patients with cancer receive radiotherapy, which often requires daily treatments for several weeks. The impact of geographic and sociodemographic factors on the odds of patients with cancer being recommended radiotherapy, starting radiotherapy, and completing radiotherapy is not well understood.This was a retrospective patient cohort study that included patients diagnosed with one of the 10 most common solid cancers from January 1, 2018, to December 31, 2021, in the National Cancer Database. The primary predictor was radial distance from a patient’s home to their cancer treatment hospital. Other covariates included baseline patient characteristics (age, sex, comorbidities, metastatic disease, cancer site), sociodemographic characteristics (race, ethnicity, median income quartile, insurance status), geographic region, and facility type. The three primary outcomes were being recommended radiotherapy, starting recommended radiotherapy, and completing radiotherapy.Of the 3,068,919 patients included, patients living >50 miles away had lower odds of being recommended radiotherapy than those living <10 miles away. Compared to White patients, Asian and Hispanic patients had lower odds of being recommended radiotherapy, and Black patients had lower odds of starting recommended radiotherapy. Uninsured patients, those with Medicaid or Medicare, and patients in lower median income quartiles had lower odds of starting or completing radiotherapy.Geographic and sociodemographic factors impact access to radiotherapy at different levels in cancer care and understanding these factors could aid policymakers and practices in identifying and supporting at‐risk patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

221. Yoga Intervention for Patients With Prostate Cancer Undergoing External Beam Radiation Therapy

Author

Ben-Josef, Avital Mazar, Wileyto, E. Paul, Chen, Jerry, and Vapiwala, Neha

Subjects
Male, Yoga, Prostatic Neoplasms, Pilot Projects, Articles, Middle Aged, prostate cancer, radiation therapy, Meditation, quality of life, Feasibility Studies, Humans, fatigue, Prospective Studies, Aged
Abstract

Purpose. Studies have demonstrated beneficial health effects from yoga interventions in cancer patients, but predominantly in breast cancer. Research on its role in alleviating prostate cancer (PC) patients’ side effects has been lacking. Our primary goal was to determine the feasibility of recruiting PC patients on a clinical trial of yoga while they underwent external beam radiation therapy (RT). Methods. Twice-weekly yoga interventions were offered throughout the RT course (6-9 weeks). Baseline demographic information was collected. Feasibility was declared if 15 of the first 75 eligible PC patients approached (20%) were successfully accrued and completed the intervention. Additional end points included standardized assessments of fatigue, erectile dysfunction (ED), urinary incontinence (UI), and quality of life (QOL) at time points before, during, and after RT. Results. Between May 2013 and June 2014, 68 eligible PC patients were identified. 23 patients (34%) declined, and 45 (56%) consented to the study. 18 (40%) were voluntarily withdrawn due to treatment conflicts. Of the remaining 27, 12 (30%) participated in ≥50% of classes, and 15 (59%) were evaluable. Severity of fatigue scores demonstrated significant variability, with fatigue increasing by week 4, but then improving over the course of treatment (P = .008). ED, UI, and general QOL scores demonstrated reassuringly stable, albeit not significant trends. Conclusions. A structured yoga intervention of twice-weekly classes is feasible for PC patients during a 6- to 9-week course of outpatient radiotherapy. Preliminary results are promising, showing stable measurements in fatigue, sexual health, UI, and general QOL.

Published
2015

222. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon

Author

Deville Curtiland, Both Stefan, Bui Viet, Hwang Wei-Ting, Tan Kay-See, Schaer Mattia, Tochner Zelig, and Vapiwala Neha

Subjects
Rectal balloon, IMRT, Toxicity, Prostate cancer, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Our purpose was to report acute gastrointestinal (GI) and genitourinary (GU) toxicity rates for prostate cancer patients undergoing image-guided intensity modulated radiation therapy (IG-IMRT) with a daily endorectal water-filled balloon (ERBH2O), and assess associations with planning parameters and pretreatment clinical characteristics. Methods The first 100 patients undergoing prostate and proximal seminal vesicle IG-IMRT with indexed-lumen 100 cc ERBH2O to 79.2 Gy in 1.8 Gy fractions at our institution from 12/2008- 12/2010 were assessed. Pretreatment characteristics, organ-at-risk dose volume histograms, and maximum GU and GI toxicities (CTCAE 3.0) were evaluated. Logistic regression models evaluated univariate association between toxicities and dosimetric parameters, and uni- and multivariate association between toxicities and pretreatment characteristics. Results Mean age was 68 (range 51–88). Thirty-two, 49, and 19 patients were low, intermediate, and high-risk, respectively; 40 received concurrent androgen deprivation. No grade 3 or greater toxicities were recorded. Maximum GI toxicity was grade 0, 1, and 2 in 69%, 23%, and 8%, respectively. Infield (defined as 1 cm above/below the CTV) rectal mean/median doses, D75, V30, and V40 and hemorrhoid history were associated with grade 2 GI toxicity (Ps Conclusion Prostate IG-IMRT using a daily ERBH2O shows low rates of acute GI toxicity compared to previous reports of air-filled ERB IMRT when using stringent infield rectum constraints and comparable GU toxicities.

Published
2012
Full Text
View/download PDF

224. Enhancing Career Paths for Tomorrow's Radiation Oncologists

Author

Vapiwala, Neha, primary, Thomas, Charles R., additional, Grover, Surbhi, additional, Yap, Mei Ling, additional, Mitin, Timur, additional, Shulman, Lawrence N., additional, Gospodarowicz, Mary K., additional, Longo, John, additional, Petereit, Daniel G., additional, Ennis, Ronald D., additional, Hayman, James A., additional, Rodin, Danielle, additional, Buchsbaum, Jeffrey C., additional, Vikram, Bhadrasain, additional, Abdel-Wahab, May, additional, Epstein, Alan H., additional, Okunieff, Paul, additional, Goldwein, Joel, additional, Kupelian, Patrick, additional, Weidhaas, Joanne B., additional, Tucker, Margaret A., additional, Boice, John D., additional, Fuller, Clifton David, additional, Thompson, Reid F., additional, Trister, Andrew D., additional, Formenti, Silvia C., additional, Barcellos-Hoff, Mary-Helen, additional, Jones, Joshua, additional, Dharmarajan, Kavita V., additional, Zietman, Anthony L., additional, and Coleman, C. Norman, additional

Published
2019
Full Text
View/download PDF

226. It starts at the top: An analysis of female representation in academic medical oncology (MO), radiation oncology (RO), and surgical oncology (SO) program leadership positions.

Author

Chowdhary, Mudit, primary, Chowdhary, Akansha, additional, Patel, Kirtesh R., additional, Royce, Trevor J., additional, Sen, Neilayan, additional, Barry, Parul Nafees, additional, Jain, Shikha, additional, Rao, Ruta D., additional, Levy, Mia Alyce, additional, Knoll, Miriam, additional, Vapiwala, Neha, additional, Wang, Dian, additional, Pro, Barbara, additional, and Marwaha, Gaurav, additional

Published
2019
Full Text
View/download PDF

229. The Impact of Graduates' Job Preferences on the Current Radiation Oncology Job Market

Author

Chowdhary, Mudit, primary, Switchenko, Jeffrey M., additional, Sen, Neilayan, additional, Chhabra, Arpit M., additional, Katz, Leah M., additional, Jegadeesh, Naresh K., additional, Barry, Parul N., additional, Wang, Dian, additional, Royce, Trevor J., additional, Curran, Walter J., additional, Vapiwala, Neha, additional, Wilson, Lynn D., additional, Abrams, Ross A., additional, Marwaha, Gaurav, additional, and Patel, Kirtesh R., additional

Published
2019
Full Text
View/download PDF

233. Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial

Author

Jayadevappa, Ravishankar, primary, Chhatre, Sumedha, additional, Gallo, Joseph J., additional, Wittink, Marsha, additional, Morales, Knashawn H., additional, Lee, David I., additional, Guzzo, Thomas J., additional, Vapiwala, Neha, additional, Wong, Yu-Ning, additional, Newman, Diane K., additional, Van Arsdalen, Keith, additional, Malkowicz, S. Bruce, additional, Schwartz, J. Sanford, additional, and Wein, Alan J., additional

Published
2019
Full Text
View/download PDF

238. The American Society for Radiation Oncology 2017 Radiation Oncologist Workforce Study

Author

Fung, Claire Y., primary, Chen, Erli, additional, Vapiwala, Neha, additional, Pohar, Surjeet, additional, Trifiletti, Daniel, additional, Truong, Minh-Tam, additional, Uschold, George, additional, Schuster, Jessica, additional, Patel, Akshar, additional, Jani, Ashesh, additional, Mohindra, Pranshu, additional, Sanders, Tim, additional, Gardner, Liz, additional, Arnone, Anna, additional, and Royce, Trevor, additional

Published
2019
Full Text
View/download PDF

239. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

Author

Narayan, Vivek, primary, Gladney, Whitney, additional, Plesa, Gabriela, additional, Vapiwala, Neha, additional, Carpenter, Erica, additional, Maude, Shannon L., additional, Lal, Priti, additional, Lacey, Simon F., additional, Melenhorst, Jan Joseph, additional, Sebro, Ronnie, additional, Farwell, Michael, additional, Hwang, Wei-Ting, additional, Moniak, Michael, additional, Gilmore, Joan, additional, Lledo, Lester, additional, Dengel, Karen, additional, Marshall, Amy, additional, Coughlin, Christina Marie, additional, June, Carl H., additional, and Haas, Naomi B., additional

Published
2019
Full Text
View/download PDF

242. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline

Author

Bekelman, Justin E., primary, Rumble, R. Bryan, additional, Chen, Ronald C., additional, Pisansky, Thomas M., additional, Finelli, Antonio, additional, Feifer, Andrew, additional, Nguyen, Paul L., additional, Loblaw, D. Andrew, additional, Tagawa, Scott T., additional, Gillessen, Silke, additional, Morgan, Todd M., additional, Liu, Glenn, additional, Vapiwala, Neha, additional, Haluschak, John J., additional, Stephenson, Andrew, additional, Touijer, Karim, additional, Kungel, Terry, additional, and Freedland, Stephen J., additional

Published
2018
Full Text
View/download PDF

246. Stigma, beliefs and perceptions regarding prostate cancer among Black and Latino men and women.

Author

Vapiwala, Neha, Miller, David, Laventure, Brenda, Woodhouse, Kristina, Kelly, Sheila, Avelis, Jade, Baffic, Cordelia, Goldston, Rodney, and Glanz, Karen

Subjects
*HEALTH equity, *PROSTATE cancer, *AFRICAN Americans, *HISPANIC Americans, *ETHNIC groups
Abstract

Background: Health disparities in prostate cancer (PC) are thought to reflect the complex interplay of socioeconomics, environment and biology. The potential impact of beliefs and perceptions about PC among Black and Latino populations on clinical disparities are not well understood. This qualitative study was conducted to assess current prevalent and pervasive stigma, beliefs and perceptions regarding PC among Blacks and Latinos living in a large metropolitan area, thereby identifying potentially modifiable barriers to care.Methods: Qualitative data were collected through four separate focus groups of self-identified Black and Latino adult men and women living in Philadelphia to better understand their perceptions of PC diagnosis, screening and treatment. Each focus group was single-sex and conducted by racial/ethnic group in order to assess possible differences in beliefs about PC based on gender and racial/ethnic affiliation. Audio recordings were transcribed verbatim by trained research assistants and qualitative data analysis was conducted using modified grounded theory.Results: There were a total of 34 participants: 19 Hispanics/Latinos and 15 Blacks, with equal numbers of men and women (n=17). Median age was 57 years (range: 18 to 85 years). Dominant themes that emerged with respect to PC diagnosis included the stigma surrounding this condition and the perceived role of an "unhealthy lifestyle" and certain sexual behaviors as risk factors for PC development. While the majority of participants acknowledged the importance of PC screening and early detection, discussion centered around the barriers to both the interest in seeking medical care and the likelihood of securing it. These barriers included misunderstanding of PC etiology, distrust of the medical profession, and financial/access limitations. Men expressed substantial confusion about PC screening guidelines. In the Black female group, the role of faith and religion in the course of disease was a major theme. Both Black and Latina females discussed the role of fear and avoidance around PC screening and treatment, as well as the prevalence of misinformation about PC in their familial and social communities.Conclusion: Black and Latino focus groups revealed the existence of cultural beliefs, misunderstandings and fears pertaining to PC which could influence health-related behaviors. Some themes were common across groups; others suggested racial and gender predilections. Future targeted efforts focused on directly addressing prevalent misperceptions among underserved communities in urban settings could help to improve health literacy and equity in PC outcomes in these populations. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

247. Comparative Analysis of 5-Year Clinical Outcomes and Patterns of Failure of Proton Beam Therapy Versus Intensity Modulated Radiation therapy for Prostate Cancer in the Postoperative Setting.

Author

Barsky, Andrew R., Carmona, Ruben, Verma, Vivek, Santos, Patricia M.G., Both, Stefan, Bekelman, Justin E., Christodouleas, John P., Vapiwala, Neha, and Deville, Curtiland

Abstract

Although proton beam therapy (PBT) is a rapidly expanding modality to treat prostate cancer compared with intensity modulated radiation therapy (IMRT), data comparing disease control outcomes and patterns of failure in the postprostatectomy setting remain substantially limited. All patients who underwent postoperative IMRT or PBT to the prostate bed only at a single institution were included (2009-2017). Endpoints included biochemical failure (BF; using institutional and recent cooperative group trial definitions), local failure (LF), regional failure (RF), distant failure (DF), and all-cause mortality. A case-matched cohort analysis was performed using 3-to-1 nearest-neighbor matching; multivariable Cox proportional hazards modeling (MVA) estimated hazard ratios for disease-related outcomes by treatment modality. Of 295 men, 260 were matched (n = 65 PBT, 195 IMRT); after matching, only age at diagnosis (P <.01) significantly differed between cohorts. At a median follow-up of 59 months, BF (institution-defined), LF, RF, DF, and mortality rates were 45% (n = 29), 2% (n = 1), 9% (n = 6), 9% (n = 6), and 2% (n = 1) for PBT, and 41% (n = 80), 3% (n = 5), 7% (n = 13), 9% (n = 18), and 5% (n = 9) for IMRT (all P >.05). RT modality was not significantly associated with BF on MVA using institutional or cooperative group definitions (all P >.05), nor with LF (P =.82), RF (P =.11), DF (P =.36), or all-cause mortality (P =.69). Patterns of failure were qualitatively similar between cohorts (DF: bone, retroperitoneal nodes, lung). In this single institution, case-matched analysis, PBT yielded similar long-term disease-related outcomes and patterns of failure to IMRT in the postprostatectomy setting. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

249. US Radiation Oncologists (Re)Defined: An American Society for Radiation Oncology Scope of Practice Study.

Author

Fung, Claire Y., Vapiwala, Neha, Mattes, Malcolm D., Mohindra, Pranshu, Shah, Chirag, Yechieli, Raphael, Truong, Minh-Tam, Sanders, Tim, Arnone, Anna, Royce, Trevor J., and Ennis, Ronald D.

Subjects
*ONCOLOGISTS, *CANCER treatment, *RADIATION, *KNOWLEDGE gap theory, *ONCOLOGY
Abstract

Purpose: To assess US radiation oncologists' views on practice scope and the ideal role of the radiation oncologist (RO), the American Society for Radiation Oncology (ASTRO) conducted a scope of practice survey.Methods and Materials: In spring 2019, ASTRO distributed an online survey to 3822 US RO members. The survey generated 984 complete responses (26% response rate) for analysis. Face validity testing confirmed respondents were representative of ASTRO's RO membership.Results: Nearly all respondents agreed that "ROs should be leaders in oncologic care." Respondents indicated the ideal approach to patient care was to provide "an independent opinion on radiation therapy and other treatment options" (82.5%) or "an independent opinion on radiation therapy but not outside of it" (16.1%), with only 1.4% favoring provision of "radiation therapy at the request of the referring physician" as the ideal approach. Actual practice fully matched the ideal approach in 18.2% of respondents. For the remaining majority, actual practice did not always match the ideal and comprised a mix of approaches that included providing radiation at the referring physician's request 24.0% of the time on average. Reasons for the mismatch included fear of alienating referring physicians and concern for offering an unwelcome opinion. One-fifth of respondents expressed a desire to expand the scope of service though interspecialty politics and insufficient training were potential barriers. Respondents interested in expanding scope of practice were on average earlier in their career (average years in practice 13.3) than those who were not interested (average years in practice 17.2, P < .001). Radiopharmaceuticals administration, medical marijuana and anticancer medications prescribing, and RO inpatient service represented areas of interest for expansion but also knowledge gaps.Conclusions: These results provide insight regarding US ROs' scope of practice and attitudes on the ideal role of the RO. For most ROs, to provide an independent opinion on treatment options represented the ideal approach to care, but barriers such as concern of alienating referring physicians prevented many from fully adhering to their ideal in practice. Actual practice commonly comprised a mixed approach, including the least favored scenario of delivering radiation at the referring physician's request one-quarter of the time, highlighting the influence of interspecialty politics on practice behavior. Advocacy for open communication and meaningful interdisciplinary collaboration presents an actionable solution toward a more balanced relationship with other specialties as ROs strive to better fulfill the vision of being leaders in oncologic care and being our best for our patients. The study also identified interest in expanding into nontraditional domains that offer opportunities to address unmet needs in the cancer patient's journey and elevate radiation oncology within the increasingly value-based US health care system. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results